ThromboprophylaXIs with Factor XI/XIa inhibitors for venous thromboembolism.

Bleeding occurred in 3% for both subgroups on FXI-ASO and in 8% of the patients on enoxaparin, but this difference did not reach statistical significance. 10 Further confirmatory data of factor XI/XIa inhibitors efficacy and safety is highly anticipated in ongoing, large, phase 3, randomized, controlled clinical trials, to enable more robust conclusions to be drawn in regards net clinical benefit, and especially if any signs of harm may exist.

also in 111,027 other papers